CombiMatrix Reports Preliminary Annual Growth of 171 Percent for Prenatal Testing Business | GenomeWeb

NEW YORK (GenomeWeb News) — CombiMatrix today reported preliminary revenue growth of 172 percent and 171 percent for billable prenatal tests in the fourth quarter of 2012 and full-year 2012, respectively.

In addition, the firm said that overall billable testing volumes, including its de-emphasized oncology segment, grew 21 percent and 25 percent in the quarter and full year, respectively, compared to its 2011 results.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.